Chronic Urticaria Or Hives – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Chronic Urticaria Or Hives – Pipeline Review, H2 2016’, provides an overview of the Chronic Urticaria Or Hives pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives

The report reviews pipeline therapeutics for Chronic Urticaria Or Hives by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chronic Urticaria Or Hives therapeutics and enlists all their major and minor projects

The report assesses Chronic Urticaria Or Hives therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Biofrontera AG

ELORAC, Inc.

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

GlaxoSmithKline Plc

Mabtech Limited

Mycenax Biotech Inc.

Novartis AG

Panacea Biotec Limited

Synermore Biologics Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Chronic Urticaria Or Hives Overview 7

Therapeutics Development 8

Pipeline Products for Chronic Urticaria Or Hives - Overview 8

Chronic Urticaria Or Hives - Therapeutics under Development by Companies 9

Chronic Urticaria Or Hives - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Chronic Urticaria Or Hives - Products under Development by Companies 13

Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development 14

Biofrontera AG 14

ELORAC, Inc. 15

F. Hoffmann-La Roche Ltd. 16

Genentech, Inc. 17

GlaxoSmithKline Plc 18

Mabtech Limited 19

Mycenax Biotech Inc. 20

Novartis AG 21

Panacea Biotec Limited 22

Synermore Biologics Co Ltd 23

Chronic Urticaria Or Hives - Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

BF-Derm-1 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

cidoxepin hydrochloride - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

GSK-2646264 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

JDP-205 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

ligelizumab - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

omalizumab - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

omalizumab biosimilar - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

omalizumab biosimilar - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

omalizumab biosimilar - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

omalizumab biosimilar - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

omalizumab biosimilar - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

quilizumab - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Chronic Urticaria Or Hives - Dormant Projects 50

Chronic Urticaria Or Hives - Discontinued Products 51

Chronic Urticaria Or Hives - Product Development Milestones 52

Featured News & Press Releases 52

Jun 12, 2015: Novartis reports new analysis showing Xolair improving quality of life by 78% for chronic spontaneous urticaria patients 52

Aug 28, 2014: Novartis announces that Xolair is approved in Canada as a licensed therapy for chronic idiopathic urticaria (CIU) patients unresponsive to antihistamines 53

May 07, 2014: FDA Approves Xolair for Treatment of Chronic Hives 54

Mar 21, 2014: Novartis announces US FDA approval of Xolair for chronic idiopathic urticaria 54

Mar 06, 2014: Novartis announces Xolair approved in EU as first and only licensed therapy for chronic spontaneous urticaria patients unresponsive to antihistamines 55

Jan 24, 2014: Novartis reports positive opinion from CHMP for Xolair in severe form of skin disease CSU, a debilitating form of hives and chronic itch 56

Oct 11, 2013: FDA Files Genentech’s Supplemental Biologics License Application of Xolair for Chronic Idiopathic Urticaria 58

Sep 30, 2013: Novartis to reveal landmark Phase III results of omalizumab at upcoming EADV 2013 congress 59

Jun 26, 2013: Novartis Reports New Phase III Data Showing Omalizumab Significantly Improves Itch In Patients With Severe Form Of CSU 60

Mar 20, 2013: Omalizumab Shows Promise In Eliminating Symptoms Of Chronic Urticaria, Study Finds 61

Feb 24, 2013: Genentech Reports Omalizumab Meets Primary Endpoint In Phase III Results In Patients With Chronic Form Of Hives Who Failed Standard Therapy 62

Appendix 64

Methodology 64

Coverage 64

Secondary Research 64

Primary Research 64

Expert Panel Validation 64

Contact Us 64

Disclaimer 65

List of Tables

List of Tables

Number of Products under Development for Chronic Urticaria Or Hives, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Chronic Urticaria Or Hives – Pipeline by Biofrontera AG, H2 2016 14

Chronic Urticaria Or Hives – Pipeline by ELORAC, Inc., H2 2016 15

Chronic Urticaria Or Hives – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 16

Chronic Urticaria Or Hives – Pipeline by Genentech, Inc., H2 2016 17

Chronic Urticaria Or Hives – Pipeline by GlaxoSmithKline Plc, H2 2016 18

Chronic Urticaria Or Hives – Pipeline by Mabtech Limited, H2 2016 19

Chronic Urticaria Or Hives – Pipeline by Mycenax Biotech Inc., H2 2016 20

Chronic Urticaria Or Hives – Pipeline by Novartis AG, H2 2016 21

Chronic Urticaria Or Hives – Pipeline by Panacea Biotec Limited, H2 2016 22

Chronic Urticaria Or Hives – Pipeline by Synermore Biologics Co Ltd, H2 2016 23

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Stage and Target, H2 2016 26

Number of Products by Stage and Mechanism of Action, H2 2016 28

Number of Products by Stage and Route of Administration, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 32

Chronic Urticaria Or Hives – Dormant Projects, H2 2016 50

Chronic Urticaria Or Hives – Discontinued Products, H2 2016 51

List of Figures

List of Figures

Number of Products under Development for Chronic Urticaria Or Hives, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Targets, H2 2016 25

Number of Products by Stage and Targets, H2 2016 25

Number of Products by Mechanism of Actions, H2 2016 27

Number of Products by Stage and Mechanism of Actions, H2 2016 27

Number of Products by Routes of Administration, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 29

Number of Products by Molecule Types, H2 2016 31

Number of Products by Stage and Molecule Types, H2 2016 31

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports